Advances in immune checkpoint inhibitors induced-cardiotoxicity

Immune checkpoint inhibitors (ICIs) are approved as the first-line drug for treating many cancers and has shown significant survival benefits; however, it also causes immune-related adverse events (irAEs) while activating the immune system, involving multiple organs. Among them, cardiovascular immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiang, Peng, Wenying, Wu, Jiao, Yeung, Sai-Ching Jim, Yang, Runxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995967/
https://www.ncbi.nlm.nih.gov/pubmed/36911712
http://dx.doi.org/10.3389/fimmu.2023.1130438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995967/
https://www.ncbi.nlm.nih.gov/pubmed/36911712
http://dx.doi.org/10.3389/fimmu.2023.1130438

Ejemplares similares